Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk

The FDA ' s decision stems from the review of a 5-year trial designed to evaluate cardiac risk with the weight-loss drug."We believe that the risks of lorcaserin outweigh its benefits," the FDA said.News Alerts
Source: Medscape Business of Medicine Headlines - Category: Pharmaceuticals Tags: Diabetes & Endocrinology News Alert Source Type: news